C. Erickson-Miller

发表

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.

J. Epstein, S. Moores, B. Keith, 2010, Blood.

Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects.

Mark Hurle, Andrew P Stubbs, Brian C Bond, 2005, DNA and cell biology.

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

M. Pappalardi, K. Duffy, L. Luo, 2017, The Journal of Pharmacology and Experimental Therapeutics.

in renal anemia

J. Epstein, S. Moores, B. Keith, 2016 .

Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat

W. Bao, D. Behm, R. Willette, 2010, Journal of cardiovascular pharmacology.

Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning

R. Parchment, C. Erickson-Miller, M. Huang, 1993, Toxicologic pathology.

A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.

J. Friedberg, O. Hyrien, L. Constine, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury.

R. Harris, K. Duffy, V. Haase, 2014, The Journal of clinical investigation.

Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.

M. Aivado, A. Chadderton, C. Erickson-Miller, 2010, Leukemia research.

Identification of the CD33‐related Siglec receptor, Siglec‐5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias

P. Virgo, C. Erickson-Miller, J. Hows, 2003, British journal of haematology.

Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis

K. Duffy, V. Haase, P. Kapitsinou, 2012 .

Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury.

K. Duffy, V. Haase, P. Kapitsinou, 2012, American journal of physiology. Renal physiology.

Differential Effect of Erythropoietin and GM‐CSF on Megakaryocytopoiesis from Primitive Bone Marrow Cells in Serum‐Free Conditions

C. Erickson-Miller, M. Murphy, J. Cardier, 1997, Stem cells.

Fas (CD95)- and tumor necrosis factor-mediated apoptosis in liver endothelial cells: role of caspase-3 and the p38 MAPK.

C. Erickson-Miller, J. Cardier, 2002, Microvascular research.

Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils.

P. Murdock, J. White, K. Kikly, 2000, The Journal of allergy and clinical immunology.

A hit deconstruction approach for the discovery of fetal hemoglobin inducers.

H. Eberl, A. Gilmartin, Zining Wu, 2018, Bioorganic & medicinal chemistry letters.

New benzimidazoles as thrombopoietin receptor agonists.

R. Keenan, D. Heerding, C. Erickson-Miller, 2006, Bioorganic & medicinal chemistry letters.

A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.

K. Kikly, P. Camilleri, C. Erickson-Miller, 2001, European journal of biochemistry.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

C. Erickson-Miller, Yanli Deng, V. Kitchen, 2007, Blood.

HEMATOPOIESIS - BRIEF REPORT Phase I Clinical Study of Eltrombopag, an Oral, Non-peptide Thrombopoietin Receptor Agonist

C. Erickson-Miller, Yanli Deng, V. Kitchen, 2007 .

Rapid publication Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils

P. Murdock, K. Kikly, J. R. White, 2000 .

Eltrombopag, but Not Romiplostim or Thrombopoietin, Inhibits Growth of Thrombopoietin Receptor Positive and Negative Human Leukemia Cell Lines

S. K. Rudolph, C. Erickson-Miller, D. Rusnak, 2012 .

Examination of survival, proliferation and cell surface antigen expression of human monocytes exposed to macrophage colony-stimulating factor (M-CSF).

C. Abboud, C. Erickson-Miller, J. Brennan, 1990, International journal of cell cloning.

IL‐6 Interferes with Stimulation of HPP‐CFC and Large CFU‐Mk in Conjunction with Cytokine Combinations from Primitive Murine Marrow Cells

C. Erickson-Miller, M. Murphy, J. Cardier, 1997, Stem cells.

Megakaryocyte colony‐stimulating factor (Meg‐CSF) is a unique cytokine specific for the megakaryocyte lineage

R. Parchment, C. Erickson-Miller, M. Murphy, 1993, British journal of haematology.

Evaluating energetics of erythropoietin ligand binding to homodimerized receptor extracellular domains.

D G Myszka, M. Doyle, D. Mcnulty, 2000, Methods in enzymology.

THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST

K. Duffy, C. Erickson-Miller, 2007 .

Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

R. Parchment, J. Tomaszewski, C. Erickson-Miller, 1997, Cancer Chemotherapy and Pharmacology.

Megakaryocytopoiesis and platelet production: Does stem cell factor play a role?

C. Erickson-Miller, M. Murphy, 1993, Stem cells.

Purification of human megakaryocyte colony‐stimulating factor (Meg‐CSF) from urine of aplastic anemia patients

R. Parchment, W. Dai, C. Erickson-Miller, 1991 .

Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis.

J. Luengo, K. Duffy, M. Darcy, 2001, Journal of medicinal chemistry.

Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics.

J. Luengo, S. Miller, L. Zhang, 2002, Journal of medicinal chemistry.

Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics.

J. Luengo, S. Miller, L. Zhang, 2002, Journal of medicinal chemistry.

Development of Phenotypic Screening Assays for γ-Globin Induction Using Primary Human Bone Marrow Day 7 Erythroid Progenitor Cells

Xin Zeng, Francesca Zappacosta, R. Ames, 2013, Journal of biomolecular screening.

Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.

S. Miller, K. Duffy, P. Lamb, 2005, Experimental hematology.

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

J. Luengo, S. Miller, K. Duffy, 2009, Stem cells.

An Oral, Non-Petide, Small Molecule Thrombopoietin Receptor Agonist Increases Platelet Counts in Healthy Subjects.

C. Erickson-Miller, Yanli Deng, J. Phillips, 2004 .

Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.

Stephen G. Miller, Kevin J. Duffy, J. Luengo, 2004 .

Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115.

J. Luengo, S. Miller, K. Duffy, 2004 .

Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.

J. Luengo, S. Miller, K. Duffy, 2004 .

SB 497115-GR, a Low Molecular Weight TPOR Agonist, Does Not Induce Platelet Activation or Enhance Agonist-Induced Platelet Aggregation in Vitro.

J. Erhardt, C. Erickson-Miller, P. Tapley, 2004 .

Signaling Induced by Erythropoietin and Stem Cell Factor in UT‐7/Epo Cells: Transient versus Sustained Proliferation

C. Erickson-Miller, L. Pelus, K. Lord, 2000, Stem cells.

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

M. Kawahara, A. Verma, I. Bruns, 2009, Blood.

Eltrombopag Decreases Proliferation of Human Leukemia and Lymphoma Cell Lines In Vitro.

C. Erickson-Miller, R. May, Parrish L. Payne, 2007 .

Effects of SB559457, a Novel Small Molecule Thrombopoietin Receptor (TpoR) Agonist, on Human Hematopoietic Cell Growth and Differentiation.

M. Carroll, A. Gewirtz, C. Erickson-Miller, 2004 .

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.

J. Erhardt, K. Pillarisetti, M. Aivado, 2009, Experimental hematology.

In vitro and in vivo biology of a small molecular weight Tpo receptor agonist, SB-497115

J. Luengo, K. Duffy, R. Keenan, 2005 .

DYRK3 Dual-specificity Kinase Attenuates Erythropoiesis during Anemia*

G. P. Livi, H. Prosser, D. Wojchowski, 2008, Journal of Biological Chemistry.

Interactions of dimethyl sulfoxide and granulocyte‐macrophage colony‐stimulating factors on the growth and maturation of HL‐60 cells

P. Keng, C. Abboud, C. Erickson-Miller, 1987, Journal of cellular physiology.

In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow.

R. Parchment, P. Lorusso, C. Erickson-Miller, 1994, Journal of the National Cancer Institute.

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.

Yoshiaki Washio, Junya Qu, Thau Ho, 2011, Chemistry & biology.

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors

K. Pillarisetti, L. Ottesen, C. Erickson-Miller, 2012, BMC Cancer.

Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors

K. Pillarisetti, I. El-Hariry, K. Baker, 2010, Journal of oncology.

C026 The non-peptide thrombopoietin receptor agonist Eltrombopag (SB-497115, Promacta/Revolade) does not stimulate malignant growth of bone marrow cells from patients with acute myeloid leukemia or myelodysplastic syndromes

M. Kawahara, A. Verma, U. Steidl, 2009 .

Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.

Stephen D Holmes, K. Kikly, C. Erickson-Miller, 2003, Experimental hematology.

DYRK gene structure and erythroid-restricted features of DYRK3 gene expression.

Mitch Weiss, D. Wojchowski, C. Erickson-Miller, 2005, Genomics.

GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.

D. Wojchowski, K. Duffy, C. Creasy, 2007 .

Purification of GCT cell-derived human colony-stimulating factors.

C. Abboud, C. Erickson-Miller, J. Brennan, 1988, Experimental hematology.

Macrophage colony-stimulating factor in nerve growth factor preparations.

C. Erickson-Miller, C. Frantz, R. Stach, 1988, Journal of neuroscience research.

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.

M. Head, S. Moores, G. Hofmann, 2011, Chemistry & biology.

HIMeg-1, a cell line derived from a CML patient, is capable of monocytic and megakaryocytic differentiation.

W. Dai, J. Dempsey, C. Erickson-Miller, 1995, Leukemia.

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

M. Pappalardi, K. Duffy, L. Luo, 2017, The Journal of Pharmacology and Experimental Therapeutics.

A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.

J. Friedberg, O. Hyrien, L. Constine, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.